Department of Neurology, University Hospital of Zurich, Zurich, Switzerland ; Department of Neurology, University Hospital of Bern, Bern, Switzerland.
PLoS One. 2013 Sep 5;8(9):e72697. doi: 10.1371/journal.pone.0072697. eCollection 2013.
To compare the effects of antiplatelets and anticoagulants on stroke and death in patients with acute cervical artery dissection.
Systematic review with Bayesian meta-analysis.
The reviewers searched MEDLINE and EMBASE from inception to November 2012, checked reference lists, and contacted authors.
Studies were eligible if they were randomised, quasi-randomised or observational comparisons of antiplatelets and anticoagulants in patients with cervical artery dissection.
Data were extracted by one reviewer and checked by another. Bayesian techniques were used to appropriately account for studies with scarce event data and imbalances in the size of comparison groups.
Thirty-seven studies (1991 patients) were included. We found no randomised trial. The primary analysis revealed a large treatment effect in favour of antiplatelets for preventing the primary composite outcome of ischaemic stroke, intracranial haemorrhage or death within the first 3 months after treatment initiation (relative risk 0.32, 95% credibility interval 0.12 to 0.63), while the degree of between-study heterogeneity was moderate (τ(2) = 0.18). In an analysis restricted to studies of higher methodological quality, the possible advantage of antiplatelets over anticoagulants was less obvious than in the main analysis (relative risk 0.73, 95% credibility interval 0.17 to 2.30).
In view of these results and the safety advantages, easier usage and lower cost of antiplatelets, we conclude that antiplatelets should be given precedence over anticoagulants as a first line treatment in patients with cervical artery dissection unless results of an adequately powered randomised trial suggest the opposite.
比较抗血小板和抗凝药物治疗急性颈内动脉夹层患者的卒中与死亡效果。
系统评价,贝叶斯 Meta 分析。
检索 MEDLINE 和 EMBASE 自建库至 2012 年 11 月,查阅参考文献,并与作者联系。
纳入比较抗血小板和抗凝药物治疗颈内动脉夹层患者的随机、准随机或观察性研究。
由一位研究者提取数据,另一位研究者核对。使用贝叶斯技术适当处理事件数据稀少且比较组大小不均衡的研究。
共纳入 37 项研究(1991 例患者),未发现随机对照试验。主要分析显示抗血小板治疗能显著降低治疗后 3 个月内缺血性卒中、颅内出血或死亡的复合终点事件发生率(相对危险度 0.32,95%可信区间 0.12 至 0.63),但各研究间存在中度异质性(τ(2) = 0.18)。在一项排除低质量研究的分析中,抗血小板治疗的获益程度较主要分析中有所减弱(相对危险度 0.73,95%可信区间 0.17 至 2.30)。
鉴于这些结果以及抗血小板药物在安全性、使用方便性和经济性方面的优势,我们认为,除非有充分效力的随机试验结果提示相反,否则在急性颈内动脉夹层患者中应优先选用抗血小板药物而非抗凝药物作为一线治疗。